The Alabang reader skews older than the rest of the metro and the framing is metabolic rather than aesthetic. Where a BGC message opens with body composition, an Alabang message opens with a lab result. Liver markers, an HbA1c that moved, a cardiologist who said something pointed. The interest in retatrutide here is almost always downstream of a number somebody was handed in a clinic.
I am not in a position to tell anyone what to do about that, and I will not. What I can point at is the published record. Alongside the Phase 2 obesity trial, there is a separate Phase 2a trial in metabolic dysfunction-associated steatotic liver disease that reported liver-fat findings, and that is the piece of the literature that Alabang readers actually ask about more than any other district. We cover it in the retatrutide liver research filing. It is a research finding in an investigational compound, not a treatment pathway.
The second thing that follows from the household framing is that the bloodwork line stops being optional. A panel at PHP 3,500 to 5,500 is the cheapest item in this entire budget and the only one that produces information about you rather than about a vial.